Novel Imaging Technique to Assess Gynecologic Cancer

Running, not enrolling · Phase 1

Conditions studied: Gynecologic Cancer

In brief

This study will test a new type of DCE (dynamic contrast-enhanced) MRI (magnetic resonance imaging) to see whether, compared with traditional MRI, it produces better images that provide more information about tumors, which may help doctors make better decisions about treating women who have gynecologic cancer. MRI is commonly used to detect and evaluate many types of cancer, but its slow processing speed and the risk that images will be blurred if the patient moves inside the scanner can limit its use in clinical practice. DCE MRI is a new imaging technique that uses additional computer processing to collect information continuously during scanning, which produces more detailed images faster than traditional MRI, which reduces the risk of movement-related blurring and provides important information about tumor activity. The DCE MRI scan in this study will be done in a standard MRI scanner, using a contrast agent (gadobutrol; Gadavist®) that has been approved by the FDA.

Key facts

Study ID

NCT04893434

Run by

Memorial Sloan Kettering Cancer Center

People needed

24

Starts

2021-05-13

Expected to finish

2027-05-01

Last updated by the study team

2026-04-02

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Healthy volunteers (for SA1) will be entered into the study if they meet the following criteria:
• Women aged 18 years or older.
• Willing and able to provide informed consent
• Patients (for SA2) will be entered into the study if they meet the following criteria:
• Women aged 18 years or older.
• Gynecologic cancer undergoing standard of care pelvic MRI prior to treatment
• Willing and able to provide informed consent and adhere to the study visit schedule and plan as specified in this protocol.

You may not qualify if…

• Healthy volunteers (SA1) and patients (SA2) exclusion criteria:
• History of allergic reactions to gadolinium-based contrast agents (GBCAs)
• Women of childbearing potential (WOCBP) must not be pregnant.
• Women must not be breastfeeding.
• Contraindications/risk factors to 3T MRI as per assessed by our departmental "Comprehensive MRI Screening Questionnaire" and "MRI Contrast Dye Questionnaire" (e.g. risk factors associated with magnetic field such as cardiac pacemakers, defibrillators or other devices as per standard institutional policy; and risk factors associated with GBCM such as diabetes, dialysis, breastfeeding)

Where it is running

• Memorial Sloan Kettering Bergen (All Protocol Activities) — Montvale, New Jersey, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• Memorial Sloan Kettering Nassau (All Protocol Activities) — Uniondale, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.